Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cortisol level Clear all
Completed Not applicable Interventional Results available

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

NCT01196117
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
14 days of placebo therapy, 14 days of CPAP therapy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Pain Catastrophizing as a Cause for Systemic Inflammation

NCT00823147
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Pain Catastrophizing Induction
Behavioral
Lead sponsor
Beth Darnall, PhD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 20, 2026, 9:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation

NCT00626626
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
Interventions
Clofar, Cyclophos, Alemtuzumab, Clofar, Cyclophos,Alemtuzumab(Ph II)
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 20, 2026, 9:41 PM EDT
Not listed No phase listed Observational

Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids

NCT05246085
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cortisol level
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer

NCT02609880
View directory record Official record
Conditions
Genital Neoplasms, Female, Insomnia, Pain, Adaptation, Psychological
Interventions
Cognitive Behavioral Therapy, Psychoeducation
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

NCT00041899
View directory record Official record
Conditions
Healthy
Interventions
CDB-2914, COB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 9:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

NCT00354107
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
Interventions
monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide, carboplatin, etoposide, methotrexate, cytarabine, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Affectionate Communication as a Response to Acute Stress

NCT00468572
View directory record Official record
Conditions
Stress
Interventions
Affectionate Writing, Meaningless Writing
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

NCT01861002
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
Interventions
Azacytidine, Fludarabine, Cytarabine, Intrathecal (IT) Cytarabine, Intrathecal Methotrexate (IT MTX)
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 20, 2026, 9:41 PM EDT
Completed No phase listed Observational

Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis

NCT00615862
View directory record Official record
Conditions
Sepsis, Alcoholism
Interventions
Observational study; no interventions
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 9:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Fruit Juices on Hormone Metabolism

NCT02187328
View directory record Official record
Conditions
Cortisol
Interventions
Grapefruit juice, Apple juice
Other
Lead sponsor
Benedictine University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lisle, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

NCT00171951
View directory record Official record
Conditions
Cushing Disease
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 20, 2026, 9:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
View directory record Official record
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

NCT02716818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, standard glucocorticoid therapy
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

NCT05063994
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort, Cortef, Placebo
Drug · Other
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 9:41 PM EDT
Withdrawn Phase 2 Interventional

Androgen Reduction in Congenital Adrenal Hyperplasia

NCT03548246
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 9 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 20, 2026, 9:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Intelligent Intensive Care Unit

NCT02465307
View directory record Official record
Conditions
Delirium, Confusion
Interventions
Confusion Assessment Method, Accelerometer, Commercially available camera, Internet Pod (iPod), Cortisol Swab
Behavioral · Device · Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 9:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Houston Independent School District (HISD) Yoga Evaluation

NCT02606591
View directory record Official record
Conditions
Health and Wellness
Interventions
Electroencephalograph, Cognitive Tests, Hair Sample
Procedure · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
8 Years to 11 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 20, 2026, 9:41 PM EDT
Recruiting No phase listed Observational

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

NCT06344143
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Various labs and imaging tests
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 9:41 PM EDT
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

NCT02270788
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Crenolanib, Sorafenib, methotrexate, hydrocortisone and cytarabine with leucovorin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 20, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628
View directory record Official record
Conditions
Leukemia, Mast-Cell, Mantle-cell Lymphoma
Interventions
Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 76 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 20, 2026, 9:41 PM EDT